Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer announces FDA approval of Geodon

Pfizer announces FDA approval of Geodon

23rd November 2009

Pfizer revealed this week that the Food and Drug Administration (FDA) has approved Geodon (ziprasidone) for use in patients with bipolar I disorder.

The drug is to be used as an adjunct to lithium and valproate in adults.

This approval comes following clinical trials which showed that Geodon is effective and well-tolerated in the long-term controlling of the disorder.

Geodon, with a combination of either lithium or valproate, was found to be a more effective treatment than placebo plus lithium or valproate in prolonging the time between mood episodes.

Charles Bowden, clinical professor of psychiatry and pharmacology, University of Texas Health Science Center, stated: “The FDA approval of Geodon provides an additional treatment option for patients with bipolar disorder, who require maintenance therapy to keep the symptoms of the disease under control.”

Meanwhile, earlier this month, Pfizer announced the establishment of its new global research and development network, which will see it develop new areas of expertise following its recent merger with Wyeth.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.